JAX Awarded $30M to Innovate Drug Safety Testing
Slice of Healthcare Team
12/09/2025
Key highlights
- $30M contract to improve drug safety with AI
- CARDIOVERSE project to create virtual hearts
- Reduction of large-animal studies
- Faster FDA approvals for new therapies
- Enhanced patient safety through better predictions
Source: PR Newswire
Notable Quotes
“ This is a moonshot vision. Imagine a future where computational models predict drug safety so reliably that it becomes ethical to move forward on computational evidence alone. It will be a big win if we can surrogate large-animal studies with a state-of-the-art computational platform. ”
Matt Mahoney, Computational Biologist at JAX
“ With CARDIOVERSE, we're building virtual hearts that more accurately reflect the broad genetic backgrounds of real people. ”
Lon Cardon, President and CEO at JAX
Why this matters
This initiative positions The Jackson Laboratory at the forefront of biomedical research by using innovative technology to transform drug testing, potentially reducing costs and improving drug safety significantly. This advancement could lead to more effective and safer treatments reaching patients more quickly, addressing a critical issue in modern medicine. This development is particularly significant for the healthcare sector.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
